RxDoctor Payments Data

Shane Summers, MD

Family Medicine · Hickory, NCNPI 1497751671

Payments from drug & device makers

$4,386in general payments, 2019–2025

Across 280 payments — averaging $15.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$432
  • AbbVie$373
  • GSK$312
  • AstraZeneca$303
  • Johnson & Johnson$277
  • Supernus Pharmaceuticals, Inc.$251
  • plus $2K from 38 others

What the payments were for

  • Food & beverage$4,30998%
  • Education$772%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,386 in reported general payments places this provider in the 85th percentile of 3,444 family medicine providers in North Carolina.

See all family medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$99,624
Medicare patients
182
Services billed
1,639

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide175$299,575
EliquisApixaban126$130,197
MounjaroTirzepatide103$128,017
JardianceEmpagliflozin79$83,944
Trelegy ElliptaFluticasone/Umeclidin/Vilanter53$60,643
MyrbetriqMirabegron46$43,320
FarxigaDapagliflozin Propanediol36$40,318
Tresiba Flextouch U-200Insulin Degludec33$34,278
XareltoRivaroxaban30$32,250
Soliqua 100-33Insulin Glargine/Lixisenatide25$24,590
Breo ElliptaFluticasone/Vilanterol38$22,378
KerendiaFinerenone15$20,449
LinzessLinaclotide18$19,843
EntrestoSacubitril/Valsartan14$19,131
Repatha SureclickEvolocumab16$18,058

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$432$299,575175 claims
PfizerEliquis$244$130,197126 claims
Lilly USA, LLCMounjaro$195$128,017103 claims
Boehringer IngelheimJardiance, Spiriva Respimat$112$91,68091 claims
GSKTrelegy Ellipta, Breo Ellipta$312$83,02191 claims
AstraZenecaFarxiga, Symbicort$303$51,03057 claims
Astellas Pharma US IncMyrbetriq$196$43,32046 claims
Johnson & JohnsonXarelto$277$32,25030 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$79$24,59025 claims
AbbVieLinzess, Synthroid$373$22,99559 claims
BayerKerendia$151$20,44915 claims
NovartisEntresto$33$19,13114 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,444 family medicine providers in North Carolina.

Other family medicine in Hickory

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →